AiCuris Anti-infective Cures GmbH
AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. Since November 2017, the first product from AiCuris is on the market. PREVYMIS™ (letermovir), designed to inhibit the viral terminase of the human cytomegalovirus (CMV), was licensed to MSD and achieved market approval in the US, Europe and Japan for the prophylaxis of CMV infections in recipients of bone marrow transplants.
Further clinical programs include Pritelivir, a helicase-primase inhibitor, developed to treat recurrent herpes simplex and AIC649, a novel biological immunomodulator targeting Hepatitis B cure and Covid-19.
AiCuris at a glance:
| Field of Activity | Anti-infectives incl. antivirals (HCMV, HSV, Hepatitis B virus, SARS-CoV-2, Adenovirus) and antibacterials (fighting AMR).Pandemic & Resistance Emergency Preparedness – PREP Program |
| Ownership Structure and Financing | Private investors, led by the family office of the Dres. Strüngmann, former owners of Hexal. |
| Partners | Merck & Co. (MSD): Licensee of Letermovir, Lysando, Max-Planck-Institute, ICIQ, Cyclenium and others. AiCuris intends to move its projects to clinical PoC before licensing/partnering. Active in-licensing strategy for pre-clinical and early clinical projects. Company incubator (AiCubator) for early projects initated in 2020. |
| Products / Services | AiCuris‘ Clinical Programs: Letermovir (licensed to MSD): HCMV, marketed (HSCT), Ph 3 (SOT) Pritelivir, HSV resistant, Phase 2/3 AIC649, Hepatitis B Virus,Phase 1 & SARS-CoV-2 treatment Several preclinical approaches in the field of AMR and antivirals |
| Unique Selling Point | Clear focus on Anti-infectives. Highly innovative antibiotic and antiviral drugs acting via new modes of action and/or from novel chemical classes. |
| Membership in networks / associations | EFPIA, BEAM Alliance, BIO Deutschland, BioRiver |
| Date of Incorporation/ Number of Employees |
2006/70 |
Contact :
| Address | Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal |
| Telephone/Telefax | +49 202 317 63 -0/-1177 |
| info@aicuris.com | |
| Web-Address | www.aicuris.com |
| Social media | LinkedIn Twitter |
- AiCuris wird zur AG, um „zukünftiges Wachstum“ zu ermöglichen – folgt das IPO?
- AiCuris-Team für den Deutschen Zukunftspreis 2018 nominiert
- Nach FDA-Zulassung: AiCuris-Wirkstoff kommt nach Europa
- AiCuris' Lizenznehmer MSD erhält FDA-Zulassung für PREVYMIS (Letermovir)
- „Die Preisvorstellung von Antibiotika muss und wird sich ändern“
- AiCuris erhält Fast-Track-Status der FDA
- Dem Horror entgegen wirken